2017 Press Releases

Keyword Search
2017 | 2016 | 2015 | 2014 | 2013
03/22/17AVEO Reports Full Year 2016 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 22, 2017-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2016 and provided a business update. “TIVO-3, our lead clinical program designed to serve as the basis for a potential U.S. registration for tivozanib as a first- and third-line treatment for renal cell cancer, continues to enroll ahead of schedule and has now completed its first safety review,” said... 
Printer Friendly Version
03/22/17AVEO Announces First Patient Dosed in Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in Advanced RCC
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 22, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in advanced renal cell carcinoma (RCC). The study, which will be led by the Institut Gustave Roussy in Paris, is under the direction of Professor Bernard Escudier, MD, Chairman... 
Printer Friendly Version
02/23/17AVEO Announces TIVO-3 Passes The First Safety Monitoring Committee Safety Review
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 23, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that its pivotal, Phase 3 TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC), has successfully completed the first safety review by the study’s Safety Monitoring Committee (SMC). The SMC concluded that no safety concern was observed for tivozani... 
Printer Friendly Version
02/09/17AVEO Announces Clinical and Regulatory Updates for Tivozanib
- Pivotal TIVO-3 Trial Enrollment Proceeding Substantially Ahead of Schedule; Enrollment Completion Expected in June - - Phase 1/2 TiNivo Trial Sites Scheduled to Open for Enrollment in Early March - - Partner EUSA Pharma Receives Day 180 List of Outstanding Issues from EMA, Oral Explanation Expected in 2Q 2017 - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 9, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced clinical and regulator... 
Printer Friendly Version
02/06/17AVEO to Present at the 19th Annual BIO CEO & Investor Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.D., Chief Medical Officer, will present at the 19th Annual BIO CEO & Investor Conference on Monday, February 13, 2017 at 8:30 AM E.T. at the Waldorf Astoria Hotel in New York City. A live webcast can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast wi... 
Printer Friendly Version